Search

Displaying results 4481 - 4490 of 10000 in total
  1. Drug

    ATHX-105

    go.drugbank.com/drugs/DB06008
    Investigational

    ATHX-105 is an investigational selective 5HT2c receptor agonist developed by Athersys Inc. for the treatment of Obesity.

  2. Drug

    Danazol

    go.drugbank.com/drugs/DB01406
    ApprovedInvestigational

    It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. … A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins.

  3. Drug

    Midomafetamine

    go.drugbank.com/drugs/DB01454
    IllicitInvestigational

    It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. … An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  4. Drug

    Ergometrine

    go.drugbank.com/drugs/DB01253
    ApprovedInvestigational

    An ergot alkaloid with uterine and vascular smooth muscle contractile properties.

    Synonyms: N-(α-(hydroxymethyl)ethyl)-D-lysergamide, N-(2-Hydroxy-1-methylethyl)-D-(+)-lysergamideCategories: Heterocyclic Compounds with 4 or More Rings, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    Pegvisomant

    go.drugbank.com/drugs/DB00082
    ApprovedInvestigational

    Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. … Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main

  6. Drug

    Zea mays pollen

    go.drugbank.com/drugs/DB10357
    Approved

    Zea mays pollen is the pollen of the Zea mays plant. Zea mays pollen is mainly used in allergenic testing.

    Mixtures: Mixture of Twenty-Two Standardized and Non-Standardized GrassesCategories: Non-Standardized Pollen Allergenic Extract
  7. Drug

    IRX-2

    go.drugbank.com/drugs/DB05643
    Investigational

    IRX-2 contains a human leukocyte-derived cytokine mixture. It is being investigated to promote or enhance an anti-cancer immune response.

    Synonyms: Cytokine-based biologic agent IRX-2
  8. Drug

    UM-171

    go.drugbank.com/drugs/DB19449
    Investigational

    UM-171 is a pyrimidoindole derivative that is an agonist of ex vivo hematopoietic stem cell expansion and thus supports the expansion of hematopoietic stem cells.[A264868, A264873]

    Synonyms: ((1r, 4r)-n1-(2-benzyl-7-(2-methyl-2h-tetrazol-5-yl)-9h-pyrimido(4,5-b)indol-4-yl)cyclohexane-1,4-diamine, Trans-n1-(7-(2-methyl-2h-tetrazol-5-yl)-2-(phenylmethyl)-9h-pyrimido(4,5-b)indol-4-yl)-1,4-cyclohexanediamineSalts: UM-171 dihydrobromide dihydrate
  9. Drug

    Olcegepant

    go.drugbank.com/drugs/DB04869
    Investigational

    Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine. … Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks

  10. Drug

    PF-06260414

    go.drugbank.com/drugs/DB15221
    Investigational

    PF-06260414 is under investigation in clinical trial NCT02070939 (Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects